Bifunctional chelating agent

Details Bifunctional chelating agent Bifunctional chelating agent

2006-11-07

2006-11-07

Le, Long V. (Department: 1641)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S405000, C530S409000, C540S474000, C436S545000, C424S009360, C424S009364, C588S020000, C588S318000, C435S188000

Reexamination Certificate

active

07132513

ABSTRACT:
The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2W is —(CH2)m— m is an integer from 1 to 10. Z is chloride, bromide or iodine

REFERENCES:
patent: 5435990 (1995-07-01), Cheng et al.
patent: 6696551 (2004-02-01), Brechbiel et al.
patent: WO 89/11475 (1989-11-01), None
patent: WO 95/20580 (1995-08-01), None
patent: WO 00/59896 (2000-10-01), None
Takenochi et al, “Preperation of bifunctional macrocyclic chelate ligands.” Japanese Patent # 03197468, 1991, HCAPLUS Accession No. 1992:128980, Document No. 116:128980.
Couturier, O., et al., “Validation of 213-Bi-alpha radioimmunotherapy for multiple myeloma”. Clin. Cancer. Res., vol. 5, pp. 3165-3170, 1999.
Huneke, R. B., et al., “Effective alpha-particle-mediated Radioimmunotherapy of Murine Leukemia”. Cancer Res., vol. 52, pp. 5818-5820, 1992.
Kozak, R. W., et al., “Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy”. Proc. Natl. Acad. Sci. USA, vol. 83, pp. 474-478, 1986.
Macklis, R. M., et al., “Radioimmunotherapy with Alpha-Particle-Emitting Immunoconjugates”. Science, vol. 240, pp. 1024-1026, 1988.
Kaspersen, F.M., et al., “Cytotoxicity of213Bi- and225Ac-immunoconjugates”. Nucl. Med. Commun., vol. 16, pp. 468-476, 1995.
Kennel, S. J. “Radioimmunotherapy of micrometastases in lung with vascular targeted 213-Bi”British Journal of Cancer. vol. 80 (1/2), pp. 175-184, 1999.
(Previously Submitted) Kaspersen, F.M. “Cytotoxicity of 213 Bi- and 225 Ac-immunoconjugates”Nuclear Medicine Communications. vol. 16, pp. 468-476, 1995.
Davis, K.A. “Comparison of 225-Actinium Chelates: Tissue Distribution and Radiotoxicity”Nuclear Medicine&Biology, vol. 26, pp. 581-589, 1999.
Grote Gransey, M.H.B. “Conjugation, Immunoreactivity, and Immunogenicity of Calix[4 ]arenas; Model Study to Potential Calix[4 ]arene-Based Ac3+ Chelators”Bioconjugate Chem. vol. 10, pp. 613-623, 1999.
Deal, Kim A., et al., “Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes”. J. Med. Chem., 42, 2988-2992, (1999).
Takenochi, K., et al., “Preparation of bifunctional macrocyclic chelate ligands”. Chemical Abstracts, vol. 116, No. 13, Abstract No. 128980, (Mar. 30, 1992).

Affiliated with

Also associated with

Rating

Bifunctional chelating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bifunctional chelating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional chelating agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3703915